Key facts
- Notable investors include Addor Capital, Jiuzhi Capital, Changxing Financial Holding, Ruiying Asset Management, Jiaxing Science and Technology City High-tech Industrial Investment — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Arthur Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Arthur Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arthur Pharma
Manufacturer of advanced pharmaceuticals intended to create generic and innovative drugs for global healthcare needs. The company offers research centers in the United States and China, diverse dosage forms including tablets, capsules, injections, and semi-solids, and international manufacturing collaborations, enabling healthcare providers worldwide to access reliable therapies for critical diseases such as cancer and diabetes.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2020
- Website
- arthurpharma.com/
- Ownership
- Privately Held (backing)
Arthur Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arthur Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arthur Pharma in its N-PORT filings yet. We sweep new filings monthly.